Curocell Inc., a cell gene therapy development company, engages in the development and manufacturing of pharmaceuticals. It provides research and development services; and OVercome Immune Suppression (OVIS), a proprietary platform technology designed to get away from exhaustion induced by immune checkpoint receptors. The company is also involved in the development of CD19 CAR-T treatment, blood cancer CAR-T, solid cancer CAR-T, and allogeneic CAR-T. Curocell Inc. was founded in 2016 and is headquartered in Daejeon, South Korea.
Frequently asked questions
What sector does Curocell (372320) operate in?
Curocell belongs to the Other sector and operates in the Biotechnology industry.
What is Curocell (372320) current stock price?
As of the latest data, Curocell stock price is ₩23,300, with a previous close of ₩23,150. Curocell gained ₩150 in the last trading session, representing a 0.65% increase.
What is Curocell (372320) current market capitalization?
Curocell market cap is approximately 354.76 billion.
What is Curocell (372320) EBITDA?
Curocell EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -14.45 billion.
Does Curocell (372320) pay dividends?
No. Curocell does not pay a dividend.
What is Curocell (372320) beta (volatility) score?
Curocell has a beta of 0.802, meaning its volatility is roughly in line with the market.